Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13743663 | 0.89 | TDP1 (0.57) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL15297525 | 0.88 | TDP1 (0.60) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL15746878 | 0.86 | TDP1 (0.63) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL13827947 | 0.86 | TDP1 (0.63) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL27777117 | 0.84 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL15244383 | 0.84 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL2062215 | 0.83 | TDP1 (0.53) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL3423605 | 0.83 | TDP1 (0.53) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL27420128 | 0.83 | EPHX1 (0.55) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL6502824 | 0.82 | TDP1 (0.49) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5393747-A | Substituted dibenzoxazepine compounds for the treatment of convulsions, ischemia and other diseases responsive to prostaglandin-E2 antagonists | G. D. SEARLE & CO. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0583408-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-02-23 | — | — | EP | claimed |
| WO-1992019605-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G. D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | claimed |
| EP-4622966-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-11241503-B2 | Oxadiazole linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20090131438-A1 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1988083-A1 | TRIAZOLE DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1798226-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-5393747-A | Substituted dibenzoxazepine compounds for the treatment of convulsions, ischemia and other diseases responsive to prostaglandin-E2 antagonists | G. D. SEARLE & CO. (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0583408-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-02-23 | — | — | EP | disclosed |
| US-5283240-A | Administering prostaglandin antagonists | G. D. SEARLE & CO. (US) | 1994-02-01 | — | — | US | disclosed |
| US-5182272-A | 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain | G. D. SEARLE & CO. (US) | 1993-01-26 | — | — | US | disclosed |
| WO-1992019605-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G. D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512399-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | TDP1 4229/4885MAOA 454/4885MAOB 258/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | TDP1 4229/4885MAOA 454/4885MAOB 258/4885 |
| US-11241503-B2 | Oxadiazole linkers and use thereof | OXA1L, CD99, IGLV6-57 | TDP1 4054/4885MAOA 1052/4885MAOB 704/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | TDP1 4229/4885MAOA 454/4885MAOB 258/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | TDP1 1600/4885MAOA 1359/4885MAOB 773/4885 |
| US-20090131438-A1 | Triazole derivative | S1PR3, S1PR1, S1PR2 | TDP1 1703/4885MAOA 3826/4885MAOB 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.